<DOC>
	<DOCNO>NCT00002792</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining bone marrow peripheral stem cell transplantation chemotherapy may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus either bone marrow peripheral stem cell transplantation treat patient myeloproliferative disorder .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Myeloproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Assess disease free survival patient idiopathic myelofibrosis treat preparative busulfan/cyclophosphamide regimen follow allogeneic bone marrow peripheral blood stem cell transplantation . - Determine risk primary graft failure patient . OUTLINE : Patients receive preparative regimen consist oral busulfan every 6 hour day -7 -4 cyclophosphamide day -3 -2 . Patients receive allogeneic bone marrow peripheral blood stem cell day 0 . Patients register protocol FHCRC-1106.00 randomized stem cell transplant receive unmodified G-CSF-mobilized stem cell HLA-identical donor . Patients receive cyclosporine/methotrexate tacrolimus/methotrexate prophylaxis graft-versus-host disease ( GVHD ) . Patients receive marrow unrelated donor eligible appropriate GVHD prophylaxis study . Patients follow 6 12 month transplant . PROJECTED ACCRUAL : A maximum 20 patient accrue study approximately 3.5 year .</detailed_description>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Idiopathic myelofibrosis ( IMF ) least 1 poor prognosis characteristic , include limited : Hemoglobin le 10 g/dL Platelet count le 100,000/mm^3 Hepatomegaly ( i.e. , palpable liver edge 5 cm costal margin ) Clinical requirement splenectomy Other myeloproliferative disorder IMF like myelofibrotic state eligible No evidence leukemic progression , e.g . : Greater 15 % peripheral blood blast Fever bone pain unknown origin Rapidly progress splenomegaly No cause myelofibrosis , : Collagen vascular disorder Lymphoma Granulomatous infection Metastatic carcinoma Hairy cell leukemia Myelodysplastic syndrome No active central nervous system disease One follow donor/patient pairing require : Donor status : Genotypic phenotypic HLAmatched relative Maximum patient age 65 One antigen HLAmismatched relative , HLAmatched unrelated donor , one antigen HLAmismatched unrelated donor Maximum patient age 55 Transplant protocol allow patient register protocol FHCRC1106.00 PATIENT CHARACTERISTICS : Age : 65 Performance status : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2 time normal SGPT great 4 time normal Renal : Creatinine great two time normal OR Creatinine clearance least 50 % Cardiovascular : Ejection fraction least 50 % Cardiac evaluation require sign symptom coronary artery disease congestive heart failure Other : HIV negative No active infection Patients exclude protocol refer protocol FHCRC179.05 PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>